PROG Progenity Inc.

2.72
-0.14  -5%
Previous Close 2.86
Open 2.87
52 Week Low 2.69
52 Week High 15.92
Market Cap $164,130,825
Shares 60,342,215
Float 18,325,169
Enterprise Value $256,691,444
Volume 389,710
Av. Daily Volume 409,602
Stock charts supplied by TradingView

Latest News

  1. SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

    The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 6146238. A live webcast and archive of the call will be available online from the investor…

    SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

    The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 6146238. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.progenity.com.

    About Progenity

    Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity's vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company's website at www.progenity.com.

    Investor Contact:

    Robert Uhl

    Managing Director, Westwicke ICR



    (619) 228-5886

    Media Contact:

    Kate Blom-Lowery

    CG Life



    (858) 457-2436



    Primary Logo

    View Full Article Hide Full Article
  2. SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced another key update regarding its Preecludia preeclampsia rule-out test. The company reported that its systems and processes necessary for commercial launch, including information systems, laboratory equipment, SOP finalization, and laboratory personnel training, all demonstrated commercial readiness as part of a pre-validation test. Additionally, data from this new, independent, prospective, naïve cohort examined as part of the pre-validation process showed test performance in the intended use population that was consistent…

    SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced another key update regarding its Preecludia preeclampsia rule-out test. The company reported that its systems and processes necessary for commercial launch, including information systems, laboratory equipment, SOP finalization, and laboratory personnel training, all demonstrated commercial readiness as part of a pre-validation test. Additionally, data from this new, independent, prospective, naïve cohort examined as part of the pre-validation process showed test performance in the intended use population that was consistent with the verification study results presented April 30th at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting. The company recently announced it is in the clinical validation testing phase for the Preecludia test, with a targeted commercial launch expected in the second half of 2021.

    Preeclampsia is the second most common cause of maternal mortality, with more than 700,000 women presenting each year with signs and symptoms of possible preeclampsia. It is characterized as a hypertensive disorder, but it is often difficult to clinically differentiate from other hypertensive conditions in pregnancy, making diagnosis and management difficult. Ultimately, left undiagnosed and improperly managed, preeclampsia can result in impaired organ function, seizures, stroke, and death in the mother, and may require pre-term delivery of the baby. Preeclampsia can result in both poor health outcomes and significant costs.

    The new data, generated with the original locked algorithm from the verification study, came from a cohort of more than 300 blinded samples equally distributed across gestational ages collected during the PRO-104 protocol, and examined as part of the pre-validation process. Analysis of these samples from the intended use population showed test performance consistent with the Preecludia verification study, indicating further de-risking of the program. The pre-validation test performance showed sensitivity greater than 87% and a negative predictive value (NPV) greater than 97% at a prevalence of 11%, and a rule out window of up to 14 days from sample collection. A similar level of performance, if observed in the larger PRO-104 validation study, would provide clinicians, especially OB/GYNs, with a new tool for their assessment of women at risk for preeclampsia. Preecludia is expected to result in a materially superior approach to the existing standard of care which offers an NPV of 83%, at best.

    "We are very encouraged by the performance of the Preecludia test as evidenced in these data and prior studies. This portends well for the future performance of Preecludia in our validation study and for when we reach the commercial market," said Harry Stylli, PhD, CEO, chairman of the board and co-founder of Progenity. "We have completed analytical testing and are initiating data analysis of the full set of patient samples from our validation study with over 1,300 patients. We plan to share the performance data from this validation study within the June/July timeframe. With these data in hand, we plan to begin a targeted launch of Preecludia in the second half of 2021 by leveraging our existing OBGYN/MFM channel."

    Progenity's Preecludia is a preeclampsia rule-out test, not a diagnostic predictive test for preeclampsia. It has the potential to be the first-of-its-kind test in the United States to help healthcare providers evaluate patients who have signs and symptoms of possible preeclampsia. This laboratory developed test (LDT) is a novel multi-analyte protein biomarker assay designed to examine markers from multiple pathophysiological pathways of preeclampsia to assess risk. It is run from a simple blood draw and is designed to address the unmet need for tools to aid in the assessment and management of preeclampsia. The US market opportunity for Preecludia is estimated at up to $3 billion, with additional global market opportunities.

    The ACOG poster presentation of the verification study results is available on the Progenity website.

    For more information about Progenity's products and pipeline visit www.progenity.com, or follow the company on LinkedIn or Twitter.

    About Progenity

    Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity's vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company's website at www.progenity.com.

    Forward Looking Statements

    This press release contains "forward-looking statements," which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the development progress of our preeclampsia rule-out test, its future use by providers to rule out preeclampsia, the performance of the rule-out test in an upcoming validation study, the completion of our upcoming validation study, and our efforts and intent to commercialize the Preecludia test and address an unmet medical need, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the forward-looking statements expressed or implied in this press release, including our ability to develop and commercialize our testing products, the size and growth potential of the markets for our products and our ability to serve those markets, the rate and degree of market acceptance and clinical utility of our products and coverage and rates of reimbursement for our products, regulatory developments in the United States and foreign countries, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our ability to improve and enhance our products, the development, regulatory approval, efficacy, and commercialization of competing products, the loss or retirement of key scientific or management personnel, our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others, the ongoing COVID-19 pandemic and associated impact on our business, and those risks described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents we file with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Robert Uhl

    Managing Director, Westwicke ICR



    (619) 228-5886

    Media Contact:

    Angela Salerno-Robin

    dna Communications



    (212) 445-8219



    Primary Logo

    View Full Article Hide Full Article
  3. Progenity survey shows more women know their baby's "fruit size" than the key indicator of a common pregnancy complication

    Preeclampsia Awareness Month aims to educate women about the potentially deadly condition and recent advancements in diagnostic risk assessment

    SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- May is Preeclampsia Awareness Month, and a recent survey is underscoring a stark need for more education around the second-most common cause of maternal mortality in the United States. The survey of nearly 800 women, including expectant mothers, new mothers within the last year, and those who are considering pregnancy, was conducted by Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success…

    Progenity survey shows more women know their baby's "fruit size" than the key indicator of a common pregnancy complication

    Preeclampsia Awareness Month aims to educate women about the potentially deadly condition and recent advancements in diagnostic risk assessment

    SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- May is Preeclampsia Awareness Month, and a recent survey is underscoring a stark need for more education around the second-most common cause of maternal mortality in the United States. The survey of nearly 800 women, including expectant mothers, new mothers within the last year, and those who are considering pregnancy, was conducted by Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women's health. The results showed less than half of respondents know that high blood pressure, the main sign of preeclampsia, is a key indicator of the condition. In contrast, more than 50 percent of respondents know the "fruit size" of a baby at 12 weeks, a popular milestone marker for moms-to-be. This survey points to the need for further patient awareness and education around the symptoms of preeclampsia, a potentially dangerous complication of pregnancy.

    Nearly 30% of pregnant women in the United States experience signs and symptoms of possible preeclampsia, a condition that can occur during pregnancy or up to six weeks after. The condition is often missed or misdiagnosed because the symptoms are common and non-specific, making it difficult for doctors to clinically distinguish between those most at risk and those at a reduced risk. If undiagnosed or poorly managed, the condition can result in impaired organ function, seizures, stroke, and even death in the infant or mother, and may require pre-term delivery. In fact, approximately 5-8% of all pregnancies are complicated by preeclampsia.

    "Early recognition of preeclampsia can save lives," said Eleni Tsigas, CEO of the Preeclampsia Foundation. "This survey shows us how much work still needs to be done to educate pregnant women about the signs and symptoms of this devastating condition. All women need to know their risk for preeclampsia because timely diagnosis and management is critical."

    It can be difficult to evaluate suspected preeclampsia because there are more than a dozen signs and symptoms that can differ from woman to woman. The two main signs—high blood pressure and protein in the urine—typically aren't noticed without a visit to the doctor. Additionally, risk factors vary, and include common features such as first pregnancy, obesity, diabetes, maternal age younger than 18 or older than 35, and family history of preeclampsia. Black women are also at higher risk, and new research points to an increase in preeclampsia and preterm birth in women diagnosed with COVID-19.

    "I wish I would have known what preeclampsia is, what the symptoms are, and the impact that it could have on my son's life and mine. Instead, I found out about preeclampsia through surviving it and delivering my son early at 28 weeks," said preeclampsia survivor, Jasmine Mago. "Now I live to raise awareness, provide education, and support research in hope that mortality rates will decrease and that there will be more progress in treatment and diagnosis."

    Despite the increasing rates of preeclampsia, there have been no significant advancements in diagnostic assessment tools in the United States in decades. However, doctors may soon have a reliable way to rule out the risk of preeclampsia for up to 14 days, modernizing the way they evaluate patients. Developed by Progenity, a proprietary lab test—called Preecludia—could potentially be a tool to help providers differentiate patients with symptoms who are not at risk for preeclampsia from those who may be at increased risk. The test is designed to be run from a simple blood draw.

    "There's a clear unmet need for additional tools to help rule out possible preeclampsia in expectant mothers, and I know this first-hand after almost losing my wife to preeclampsia after a missed diagnosis," said Matthew Cooper, Ph.D., Chief Scientific Officer, Progenity. "The Preecludia test would be the first of its kind in the United States and would help to fill a gap in the assessment and management of preeclampsia. We look forward to offering the test to physicians and patients to make a real difference in the lives of mothers and babies."

    For more information about preeclampsia and how to recognize its signs and symptoms, visit the Preeclampsia Foundation.

    For more information about Progenity's products and pipeline visit www.progenity.com, or follow the company on LinkedIn or Twitter.

    About Preecludia

    Progenity's preeclampsia rule-out test, Preecludia, has the potential to be the first-of-its-kind test in the United States to help healthcare providers evaluate patients who have signs and symptoms of possible preeclampsia. This laboratory developed test (LDT) is a novel multi-analyte protein biomarker assay designed to examine markers from multiple pathophysiological pathways of preeclampsia to assess risk. It is run from a simple blood draw and is designed to address the unmet need for tools to aid in the assessment and management of preeclampsia. Positive performance data from the Preecludia verification study were presented April 30th at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting. The test is now in the final clinical validation testing phase, with a targeted launch expected in the second half of 2021   

    About Progenity

    Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity's vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, please visit progenity.com.

    About the Preeclampsia Foundation

    The Preeclampsia Foundation is a U.S.-based 501(c)(3) not-for-profit organization established in 2000. Its purpose is to improve the outcomes of hypertensive disorders of pregnancy by educating, supporting and engaging the community, improving healthcare practices, and finding a cure. The Preeclampsia Foundation envisions a world where hypertensive disorders of pregnancy no longer threaten the lives of mothers and their babies. For more information, visit www.preeclampsia.org.

    Forward Looking Statements

    This press release contains "forward-looking statements," which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the development progress of our preeclampsia rule-out test, and its future use by providers to rule out preeclampsia, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the forward-looking statements expressed or implied in this press release, including acceptance and clinical utility of our products, regulatory developments in the United States and foreign countries, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, and those risks described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents we file with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Robert Uhl

    Managing Director, Westwicke ICR



    (619) 228-5886

    Media Contact:

    Angela Salerno-Robin

    dna Communications



    (212) 445-8219



    Primary Logo

    View Full Article Hide Full Article
  4. SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced new data from its Preecludia preeclampsia rule-out test verification study are being presented today at the 2021 ACOG Annual Meeting, with the test demonstrating sensitivity of 87.8% and a negative predictive value (NPV) of 97.0%. The company recently announced it is in the clinical validation testing phase of Preecludia, with a targeted launch expected in the second half of 2021.

    Preeclampsia is the second most common cause of maternal mortality, with more than 700,000 women presenting each year with signs and symptoms…

    SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced new data from its Preecludia preeclampsia rule-out test verification study are being presented today at the 2021 ACOG Annual Meeting, with the test demonstrating sensitivity of 87.8% and a negative predictive value (NPV) of 97.0%. The company recently announced it is in the clinical validation testing phase of Preecludia, with a targeted launch expected in the second half of 2021.

    Preeclampsia is the second most common cause of maternal mortality, with more than 700,000 women presenting each year with signs and symptoms of possible preeclampsia. It is characterized as a hypertensive disorder, but it is often difficult to clinically differentiate it from other hypertensive conditions in pregnancy, making diagnosis and management difficult. Ultimately, if left undiagnosed and improperly managed, preeclampsia can result in impaired organ function, seizures, stroke, and death in the mother, and may require pre-term delivery of the baby. Preeclampsia can result in both poor health outcomes and significant costs.

    In the verification study being presented at ACOG today, blinded, naïve samples from twenty-four U.S. sites were tested to determine the performance of Preecludia to assess the risk of preeclampsia within fourteen days of sample collection. The samples were representative of a diverse U.S. population. Preecludia test performance, based on 303 subjects, showed 87.8% sensitivity and 97.0% NPV. These data point to the value of the test in assisting physicians to rule out patients at risk for preterm preeclampsia. By so doing, the test may provide reassurance to physicians and patients, and assist physicians in making better informed management and treatment decisions, potentially reducing overuse of interventions and resultant complications.

    "These data and prior studies are strong indicators of the future performance of the Preecludia test, and we are honored to present them at ACOG," said Harry Stylli, PhD, CEO, chairman of the board and co-founder of Progenity. "They are also particularly timely as we mark Preeclampsia Awareness Month in May. We have initiated analysis of our PRO-104 validation study patient samples and plan to share the performance data, established with samples from over 1,300 patients, in the June/July timeframe. We expect to bring our Preecludia test to market soon thereafter, to finally provide doctors and expectant women with a unique, modern solution for improving preeclampsia risk assessment."

    Preecludia has the potential to be the first-of-its-kind test in the United States to help healthcare providers evaluate patients who have signs and symptoms of possible preeclampsia. This laboratory developed test (LDT) is a novel multi-analyte protein biomarker assay designed to examine markers from multiple pathophysiological pathways of preeclampsia to assess risk. It is run from a simple blood draw and is designed to address the unmet need for tools to aid in the assessment and management of preeclampsia. The U.S. market opportunity is for Preecludia is estimated at up to $3 billion, with additional global market opportunities.

    The data presented at ACOG are part of the virtual meeting's interactive ePosters. Details of the presentation are as follows:

    Title – Performance of a novel multi-biomarker rule out preeclampsia test: a prospective verification study

    Authors – Matthew Cooper, PhD, DABT, MBA; Amin Mazloom, PhD; Chelsea Obrochta, PhD(c); Ronald Wapner, MD; Todd Rosen, MD; Allan Bombard, MD

    Poster number 999251

    The poster presentation will also be made available on the Progenity website following the conference.

    For more information about Progenity's products and pipeline visit www.progenity.com, or follow the company on LinkedIn or Twitter.

    About Progenity

    Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity's vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company's website at www.progenity.com.

    Forward Looking Statements

    This press release contains "forward-looking statements," which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the development progress of our preeclampsia rule-out test, its future use by providers to rule out preeclampsia, the performance of the rule-out test in an upcoming validation study, the completion of our upcoming validation study, and our efforts and intent to commercialize the Preecludia test and address an unmet medical need, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the forward-looking statements expressed or implied in this press release, including our ability to develop and commercialize our testing products, the size and growth potential of the markets for our products, and our ability to serve those markets, the rate and degree of market acceptance and clinical utility of our products and coverage and rates of reimbursement for our products, regulatory developments in the United States and foreign countries, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our ability to improve and enhance our products, the fact that the data presented relates to the verification stage and may not be predicative of future results, including those from the validation stage, the development, regulatory approval, efficacy, and commercialization of competing products, the loss or retirement of key scientific or management personnel, our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others, the ongoing COVID-19 pandemic and associated impact on our business, and those risks described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents we file with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Robert Uhl

    Managing Director, Westwicke ICR



    (619) 228-5886

    Media Contact:

    Angela Salerno-Robin

    dna Communications



    (212) 445-8219



    Primary Logo

    View Full Article Hide Full Article
  5. SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that two abstracts related to Progenity's ingestible drug delivery technologies for the treatment of gastrointestinal disorders have been accepted for presentation at Digestive Disease Week® (DDW). The DDW Virtual Meeting, taking place May 21-23, 2021, is the world's premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

    Details of the presentations are as follows:

    Session Title: Animal Models: Pre-Clinical Treatment of Intestinal…

    SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that two abstracts related to Progenity's ingestible drug delivery technologies for the treatment of gastrointestinal disorders have been accepted for presentation at Digestive Disease Week® (DDW). The DDW Virtual Meeting, taking place May 21-23, 2021, is the world's premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

    Details of the presentations are as follows:

    Session Title: Animal Models: Pre-Clinical Treatment of Intestinal Inflammation

    Session Date & Time: May 21, 2021 from 12:15 PM to 1:00 PM Eastern

    Presentation Title: Targeted Delivery of Soluble Tofacitinib Citrate to the Site of Inflammation to Improve Efficacy and Safety

    Session Title: Imaging Techniques and Technologies in GI

    Session Date & Time: May 23, 2021 from 12:15 PM to 1:00 PM Eastern

    Presentation Title: Development of a Novel Drug Delivery System 2 (DDS2) for Colon Targeted Delivery Treatment of Ulcerative Colitis (UC)

    The study findings will be a part of on-demand sessions which are embargoed until 12:15 p.m. Eastern the day the ePoster is presented. More information about these abstracts will be made available on the Progenity website following the conference.

    About Progenity

    Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity's vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

    For more information about Progenity's products and pipeline visit www.progenity.com, or follow the company on LinkedIn or Twitter.

    Investor Contact:

    Robert Uhl

    Managing Director, Westwicke ICR



    (619) 228-5886

    Media Contact:

    Kate Blom-Lowery

    CG Life



    (619)743-6294



    Primary Logo

    View Full Article Hide Full Article
View All Progenity Inc. News